Neomycin inhibits secretion of apolipoprotein[a] by increasing retention on the hepatocyte cell surface

Journal of Lipid Research

Volumn 37, Issue 10, 1996, Pages 2055-2064

  Lanford, Robert E ^a   Estlack, Larry ^a   White, Ann L ^a  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

apolipoprotein B; lipoprotein a ; phosphatidylinositol; primary hepatocytes; serum free medium

Indexed keywords

2 DEOXYSTREPTAMINE; ANTIBIOTIC AGENT; ANTIBIOTIC G 418; APOLIPOPROTEIN A; APOLIPOPROTEIN B; GENTAMICIN; KANAMYCIN B; NEOMYCIN; PAROMOMYCIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; RIBOSTAMYCIN; TOBRAMYCIN;

ANIMAL CELL; ARTICLE; BABOON; CELL SURFACE; CULTURE MEDIUM; LIPOPROTEIN SECRETION; LIPOPROTEIN SYNTHESIS; LIVER CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; APOLIPOPROTEINS A; CELL MEMBRANE; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; IMMUNOSORBENT TECHNIQUES; KINETICS; LIVER; MOLECULAR STRUCTURE; NEOMYCIN; PAPIO; PROTEIN SYNTHESIS INHIBITORS; TRYPSIN;

EID: 0029859081     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Berg, K. 1963. A new serum type system in man-Lp system. Acta. Pathol. Microbiol. Scand. 59: 369-382.
2. Utermann, G. 1989. The mysteries of lipoprotein[a]. Science. 246: 904-910.
3. Scanu, A. M., and G. M. Fless. 1990. Lipoprotein [a]. Heterogeneity and biological relevance. J. Clin. Invest. 85: 1709-1715.
4. Liu, A. C., and R. M. Lawn. 1994. Lipoprotein[a] and atherogenesis. Trends Cardiovasc. Med. 4: 40-44.
5. Valentine, R. J., P. A. Grayburn, G. L. Vega, and S. M. Grundy. 1994. Lp[a] lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch. Intern. Med. 154: 801-806.
6. Rainwater, D. L., and R. E. Lanford. 1989. Production of lipoprotein[a] by primary baboon hepatocytes. Biochim. Biophys. Acta. 1003: 30-35.
7. Kraft, H. G., H. J. Menzel, F. Hoppichler, W. Vogel, and G. Utermann. 1989. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J. Clin. Invest. 83: 137-142.
8. Tomlinson, J. E., J. W. McLean, and R. M. Lawn. 1989. Rhesus monkey apolipoprotein[a]. Sequence, evolution, and sites of synthesis. J. Biol. Chem. 264: 5957-5965.
9. Laplaud, P. M., L. Beaubatie, S. C. Rall, Jr., G. Luc, and M. Saboureau. 1988. Lipoprotein [a] is the major apoB-containing lipoprotein in the plasma of a hibernator, the hedgehog (Erinaceus europaeus). J. Lipid Res. 29: 1157-1170.
10. Lawn, R. M., N. W. Boonmark, K. Schwartz, G. E. Lindahl, D. P. Wade, C. D. Byrne, K. J. Fong, K. Meer, and L. Patthy. 1995. The recurring evolution of lipoprotein[a]-insights from cloning of hedgehog apolipoprotein[a]. J. Biol. Chem. 270: 24004-24009.
11. Utermann, G., H. J. Menzel, H. G. Kraft, H. C. Duba, H. G. Kemmler, and C. Seitz. 1987. Lp[a] glycoprotein phenotypes. Inheritance and relation to Lp[a]-lipoprotein concentrations in plasma. J. Clin. Invest. 80: 458-465.
12. Gaubatz, J. W., K. I. Ghanem, J. Guevara, Jr., M. L. Nava, W. Patsch, and J. D. Morrisett. 1990. Polymorphic forms of human apolipoprotein [a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein [a]. J. Lipid Res. 31: 603-613.
13. Lackner, C., J. C. Cohen, and H. H. Hobbs. 1993. Molecular definition of the extreme size polymorphism in apolipoprotein[a]. Hum. Mol. Genet. 2: 933-940.
14. Marcovina, S. M., Z. H. Zhang, V. P. Gaur, and J. J. Albers. 1993. Identification of 34 apolipoprotein[a] isoforms: differential expression of apolipoprotein[a] alleles between American Blacks and Whites. Biochem. Biophys. Res. Commun. 191: 1192-1196.
15. McLean, J. W., J. E. Tomlinson, W. J. Kuang, D. L. Eaton, E. Y. Chen, G. M. Fless, A. M. Scanu, and R. M. Lawn. 1987. cDNA sequence of human apolipoprotein [a] is homologous to plasminogen. Nature. 330: 132-137.
16. Hixson, J. E., M. L. Britten, G. S. Manis, and D. L. Rainwater. 1989. Apolipoprotein [a] (apo[a]) glycoprotein isoforms result from size differences in apo[a] mRNA in baboons. J. Biol. Chem. 264: 6013-6016.
17. Lackner, C., E. Boerwinkle, C. C. Leffert, T. Rahmig, and H. H. Hobbs. 1991. Molecular basis of apolipoprotein [a] isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J. Clin. Invest. 87: 2153-2161.
18. Fless, G. M., M. E. ZumMallen, and A. M. Scanu. 1986. Physicochemical properties of apolipoprotein [a] and lipoprotein [a-] derived from the dissociation of human plasma lipoprotein [a]. J. Biol. Chem. 261: 8712-8718.
19. Kratzin, H., V. W. Armstrong, M. Niehaus, N. Hilschman, and D. Seidel. 1987. Structural relationship of an apolipoprotein [a] phenotype (570 kDa) to plasminogen: homologous kringle domains are linked by carbohydrate-rich regions. Biol. Chem. Hoppe-Seyler. 368: 1533-1544.
20. Gaubatz, J. W., G. L. Cushing, and J. D. Morrisett. 1986. Quantitation, isolation, and characterization of human lipoprotein [a]. Methods Enzymol. 129: 167-186.
21. Boerwinkle, E., C. C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H. H. Hobbs. 1992. Apolipoprotein [a] gene accounts for greater than 90% of the variation in plasma lipoprotein [a] concentrations. J. Clin. Invest. 90: 52-60.
22. Rainwater, D. L., G. S. Manis, and J. L. VandeBerg. 1989. Hereditary and dietary effects on apolipoprotein [a] isoforms and Lp[a] in baboons. J. Lipid Res. 30: 549-558.
23. Krempler, F., G. M. Kostner, and K. Bolzano. 1980. Turnover of lipoprotein[a] in man. J. Clin. Invest. 65: 1483-1490.
24. Rader, D. J., W. Cain, L. A. Zech, D. Usher, and H. B. Brewer, Jr. 1993. Variation in lipoprotein[a] concentrations among individuals with the same apolipoprotein[a] isoform is determined by the rate of lipoprotein[a] production. J. Clin. Invest. 91: 443-447.
25. Azrolan, N., D. Gavish, and J. L. Breslow. 1991. Plasma lipoprotein[a] concentration is controlled by apolipoprotein[a] (apo[a]) protein size and the abundance of hepatic apo[a] mRNA in a cynomolgus monkey model. J. Biol. Chem. 266: 13866-13872.
26. Albers, J. J., J. L. Adolphson, and W. R. Hazzard. 1977. Radioimmunoassay of human plasma Lp[a] lipoprotein. J. Lipid Res. 18: 331-338.
27. White, A. L., D. L. Rainwater, J. E. Hixson, L. E. Estlack, and R. E. Lanford. 1994. Intracellular processing of apo[a] in primary baboon hepatocytes. Chem. Phys. Lipids. 67-68: 123-133.
28. White, A. L., J. E. Hixson, D. L. Rainwater, and R. E. Lanford. 1994. Molecular basis for "null" lipoprotein[a] phenotypes and the influence of apolipoprotein[a] size on plasma lipoprotein[a] level in the baboon. J. Biol. Chem. 269: 9060-9066.
29. Rainwater, D. L., G. S. Manis, and R. S. Kushwaha. 1986. Characterization of an unusual lipoprotein similar to human lipoprotein[a] isolated from the baboon, Papio sp. Biochim. Biophys. Acta. 877: 75-78.
30. Rainwater, D. L., and G. S. Manis. 1988. Immunochemical characterization and quantitation of lipoprotein [a] in baboons. Atherosclerosis. 73: 23-31.
31. White, A. L., and R. E. Lanford. 1994. Cell surface assembly of lipoprotein[a] in primary cultures of baboon hepatocytes. J. Biol. Chem. 269: 28716-28723.
32. White, A. L., D. L. Rainwater, and R. E. Lanford. 1993. Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in baboon hepatocytes. J. Lipid Res. 34: 509-517.
33. White, A. L., and R. E. Lanford. 1995. Biosynthesis and metabolism of lipoprotein[a]. Curr. Opin. Lipidol. 6: 75-80.
34. Sedaghat, A., P. Samuel, J. R. Crouse, and E. H. Ahrens. 1975. Effects of neomycin on adsorption, synthesis and/or flux of cholesterol in man. J. Clin. Invest. 55: 12-21.
35. Gurakar, A., J. M. Hoeg, G. Kostner, N. M. Papadopoulos, and H. B. Brewer, Jr. 1985. Levels of lipoprotein Lp[a] decline with neomycin and niacin treatment. Atherosclerosis. 57: 293-301.
36. Lanford, R. E., K. D. Carey, L. E. Estlack, G. C. Smith, and R. V. Hay. 1989. Analysis of plasma protein and lipoprotein synthesis in long-term primary cultures of baboon hepatocytes maintained in serum-free medium. In Vitro Cell. Dev. Biol. 25: 174-182.
37. Rinehart, K. L. 1969. Comparative chemistry of the aminoglycoside and aminocyclitol antibiotics. J. Infect. Dis. 119: 345-350.
38. Spinler, S. A., and M. J. Cziraky. 1994. Physiological function, association with athersclerosis, and effects of lipid-lowering drug therapy. Ann. Pharmacother. 28: 343-351.
39. Sirtori, C. R., C. Manzoni, and M. R. Lovati. 1991. Mechanisms of lipid-lowering agents. Cardiology. 78: 226-235.
40. Crook, D., M. Sidhu, M. Seed, M. O'Donnell, and J. C. Stevenson. 1992. Lipoprotein Lp[a] levels are reduced by danazol, an anabolic steroid. Atherosclerosis. 92: 41-47.
41. Albers, J. J., H. M. Taggart, D. Applebaum-Bowden, S. Haffner, C. H. Chesnut, and W. R. Hazzard. 1984. Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp[a] lipoprotein with the anabolic steroid stanozolol. Biochim. Biophys. Acta. 795: 293-296.
42. Bihari-Varga, M., E. Gruber, M. Rotheneder, R. Zechner, and G. M. Kostner. 1988. Interaction of lipoprotein Lp[a] and low density lipoprotein with glycosaminoglycans from human aorta. Arteriosclerosis. 8: 851-857.
43. Salonen, E. M., M. Jauhiainen, L. Zardi, A. Vaheri, and C. Ehnholm. 1989. Lipoprotein [a] binds to fibronectin and has a serine proteinase activity capable of cleaving it. EMBO J. 8: 4035-4040.
44. Loscalzo, J., M. Weinfeld, G. M. Fless, and A. M. Scanu. 1990. Lipoprotein [a], fibrin binding, and plasminogen activation. Arteriosclerosis. 10: 240-245.
45. Armstrong, V. W., B. Harrach, H. Robenek, M. Helmhold, A. K. Walli, and D. Seidel. 1990. Heterogeneity of human lipoprotein [a]: cytochemical and biochemical studies on the interaction of two Lp[a] species with the LDL receptor. J. Lipid Res. 31: 429-441.
46. Harkes, L., G. Jurgens, A. Holasek, and T. J. C. Van Berkel. 1988. In vivo studies on the binding sites for lipoprotein [a] on parenchymal and non-parenchymal rat liver cells. FEBS Lett. 227: 27-31.
47. Thompson, G. R., J. Barrowman, L. Gutierrez, and R. H. Dowling. 1971. Action of neomycin on the intraluminal phase of lipid absorption. J. Clin. Invest. 50: 319-323.
48. Thompson, G. R., M. MacMahon, and P. Claes. 1970. Precipitation of neomycin compounds of fatty acids and cholesterol from mixed micellar solutions. Eur. J. Clin. Invest. 1: 40-47.
49. Forge, A., G. Zajic, S. Davies, N. Weiner, and J. Schacht. 1989. Gentamicin alters membrane structure as shown by freeze-fracture of liposomes. Hearing Res. 37: 129-139.
50. Riaz, M., N. D. Weiner, and J. Schacht. 1989. Separation of liposome populations differing in phosphoinositide content by chromatography on immobilized neomycin. J. Pharm. Sci. 78: 172-175.
51. Au, S., N. D. Weiner, and J. Schacht. 1987. Aminoglycoside antibiotics preferentially increase permeability phosphoinositide-containing membranes: a study with carboxyfluorescein in liposomes. Biochim. Biophys. Acta. 902: 80-86.
52. Williams, S. E., and J. Schacht. 1986. Binding of neomycin and calcium to phospholipids and other anionic compounds. J. Antibiot. 39: 457-462.
53. Tysnes, O. B., A. J. Verhoeven, and H. Holmsen. 1987. Neomycin inhibits agonist-stimulated polyphosphoinositide metabolism and responses in human platelets. Biochem. Biophys. Res. Commun. 144: 454-462.
54. Carney, D. H., D. L. Scott, E. A. Gordon, and E. F. LaBelle. 1985. Phosphoinositides in mitogenesis: neomycin inhibits thrombin-stimulated phosphoinositide turnover and initiation of cell proliferation. Cell. 42: 479-488.
55. Van Rooijen, L. A., and B. W. Agranof. 1985. Inhibition of phosphoinositide phosphodiesterase by aminoglycoside antibiotics. Neurochem. Res. 10: 1019-1024.
56. Gabev, E., J. Kasianowicz, T. Abbott, and S. McLaughlin. 1989. Binding of neomycin to phosphatidylinositol 4,5,biphosphate (PIP2). Biochim. Biophys. Acta. 979: 105-112.
57. Slivka, S. R., and P. A. Insel. 1988. Phorbol ester and neomycin dissociate bradykinin receptor-mediated arachidonic acid release and polyphosphoinositide hydrolysis in Madin-Darby canine kidney cells. Evidence that bradykinin mediates noninterdependent activation of phospholipases A2 and C. J. Biol. Chem. 263: 14640-14647.
58. Vassbotn, F. S., A. Ostman, A. Siegbahn, H. Holmsen, and C-H. Heldin. 1992. Neomycin is a platelet-derived growth factor (PDGF) antagonist that allows discrimination of PDGFα and β receptor signals in cells expressing both receptor types. J. Biol. Chem. 267: 15635-15641.
59. Langeland, N., H. Holmsen, J. R. Lillehaug, and L. Haarr. 1987. Evidence that neomycin inhibits binding of herpes simplex virus type 1 to the cellular receptor. J. Virol. 61: 3388-3393.
60. Langeland, N., A. M. Oyan, H. S. Marsden, A. Cross, J. C. Glorioso, L. J. Moore, and L. Haarr. 1990. Localization on the herpes simplex virus type 1 genome of a region encoding proteins involved in adsorption to the cellular receptor. J. Virol. 64: 1271-1277.
61. Tysnes, O., E. Johanessen, and V. M. Steen. 1991. Neomycin does not interfere with the inositol phospholipid metabolism, but blocks binding of alpha-thrombin to intact human platelets. Biochem. J. 273: 241-243.
62. Christ, M., C. Meyer, K. Sippel, and M. Wehling. 1995. Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, dicylglycerol and protein kinase C alpha. Biochem. Biophys. Res. Commun. 213: 123-129.
63. Shibanaka, Y., H. Hayashi, M. Takai, and N. Fujita. 1993. Eclosion hormone activates phosphatidylinositol hydrolysis in silkworm abdominal ganglia during adult metamorphosis. Eur. J. Biochem. 211: 427-430.